Over the Counter Drugs:

Gaps and Potential Vulnerabilities in the Regulatory System

T-PEMD-92-8: Published: Apr 28, 1992. Publicly Released: Apr 28, 1992.

Additional Materials:


Office of Public Affairs
(202) 512-4800

GAO discussed the Food and Drug Administration's (FDA) system for approving and monitoring nonprescription drugs. GAO noted that: (1) the majority of nonprescription drugs reach the market through a drug review monograph, which specifies the therapeutic categories of ingredients that are generally recognized as safe and effective and thus permissible in a given drug product, as well as dosage, labelling, and mode of administration; (2) FDA has been slow to develop monographs for nonprescription drugs, resulting in an undetermined number of products that have not been measured against generally accepted standards of safety and effectiveness; (3) FDA does not know the number of nonprescription products currently being marketed in the United States; and (4) since FDA does not have statutory authority to inspect nonprescription drug manufacturer's records, it is largely dependent on voluntary reports on monograph-controlled products from manufacturers, health providers, and consumers for post-marketing information.

Nov 18, 2020

Nov 17, 2020

Nov 13, 2020

Nov 12, 2020

Nov 4, 2020

Oct 26, 2020

Oct 8, 2020

Oct 1, 2020

Sep 30, 2020

Looking for more? Browse all our products here